EMG
CRBP icon

Ellington Management Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Ellington Management Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-690
Closed -$113K – 576
2019
Q4 		$113K Sell
690
-140
-17% -$20.7K 0.02% 488
2019
Q3 		$121K Buy
830
+27
+3% +$4.7K 0.02% 546
2019
Q2 		$167K Sell
803
-154
-16% -$33K 0.03% 510
2019
Q1 		$199K Buy
+957
New +$211K 0.04% 479
2018
Q2 		– Sell
-690
Closed -$126K – 563
2018
Q1 		$126K Buy
+690
New +$155K 0.01% 772

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ellington Management Group's CRBP Position: Q1 2020 in Review

Ellington Management Group sold out of Corbus Pharmaceuticals (CRBP) in Q1 2020, closing a stake of 690 shares — an estimated $113K sold.

Ellington Management Group first reported a position in CRBP in Q1 2018 and held it in 5 quarters. The position peaked at $199K in Q1 2019. 111 funds tracked by Wall St. Rank hold CRBP as of Q1 2020.

  • Ellington Management Group reported no remaining Corbus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Ellington Management Group sold 690 Corbus Pharmaceuticals shares in Q1 2020, an estimated $113K.
  • Ellington Management Group first reported a position in Corbus Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Ellington Management Group's Corbus Pharmaceuticals position peaked at $199K in Q1 2019.
  • 111 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2020.

Based on Ellington Management Group's 13F filing for Q1 2020, filed 15 May 2020.